India's leading pharmaceutical firm, Ranbaxy Laboratories has informed that it has suffered a huge drop in its profit-after-tax figure in the June quarter of the current fiscal year.

The company has announced its financial results for first quarter of the fiscal year 2010-11. As per the report, its profit-after-tax has declined almost 48.2% in the first quarter of the year.

The PAT of the firm was reported to be $72 million (Rs 332 crore) for the quarter that ended on 30th of June in the current year. For the same period of time, the PTA was $139 million (Rs 693.1 crore) in the previous year. Ranbaxy Laboratories has informed this fact to the Bombay Stock Exchange in a filing.

However, there has been a hike in the consolidated sales of the company. It has gone up 24.5% in the quarter under review against its like period a year ago.

Ranbaxy Laboratories consolidated sales during the April-June quarter has been recorded $458 million (Rs 2,102.9 crore). It was $368 million (Rs 1,795.3 crore) in the year-ago period.